Glaukos (GKOS) Stock Forecast & Price Target

Glaukos is well-positioned to see strong growth in the coming years, driven by its innovative and first-of-its-kind iDose TR implant for glaucoma and its proprietary bio-activated pharmaceutical therapy for keratoconus. With an impressive pipeline in retinal diseases and other potential market opportunities, the company is likely to become a much larger player in the ophthalmic pharmaceutical and medical technology industry in the near future. The company's positive outlook is further supported by the high-volume and expected growth of SLT/DSLT physicians, potential upside in iDose sales, and increasing usage of the doctors' preferred alternatives, such as Canaloplasty or Alloflo. While there may be challenges with the company's potential LCD outcome, Epioxa is expected to drive growth and could potentially offset any potential impact on iDose revenues. Our bullish outlook for Glaukos includes strong double-digit revenue growth, with little to no impact from the iDose LCD and ramping Epioxa coverage and case volumes. However, in a bear case scenario, with iDose being materially impacted by LCDs and potential disappointment in Epioxa volumes, the stock could see a decline in price.

Glaukos is facing numerous challenges that could negatively impact its sales, such as the potential limitations and restrictions imposed by the proposed iDose LCDs and the increasing competition in the market. This potential LCD could significantly restrict the use of iDose, which may impact patients' access to this effective treatment. Additionally, the proposed restrictions and requirements on combining iDose with other procedures may reduce utilization and limit revenue potential. Furthermore, there are concerns regarding reimbursement as payers and physicians may push back on Epioxa pricing and there is uncertainty around the outcome of the LCD process. This could lead to delayed treatment and poor adherence, ultimately hindering sales growth prospects. Moreover, Glaukos may face challenges with its pipeline products and MIGS market share losses. This, combined with the high costs of surgery and administrative burden, may limit the company's financial performance in the long run. Overall, the increasing challenges and risks faced by Glaukos, particularly with the potential restrictions on iDose, make for a negative outlook on the company's stock. This could result in decreased sales and financial performance in the future.